<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="233260">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00038727</url>
  </required_header>
  <id_info>
    <org_study_id>IND - DK048489</org_study_id>
    <nct_id>NCT00038727</nct_id>
    <nct_alias>NCT00353314</nct_alias>
  </id_info>
  <brief_title>Diabetes Prevention Program Outcomes Study</brief_title>
  <acronym>DPPOS</acronym>
  <official_title>Diabetes Prevention Program Outcomes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Research on Women's Health (ORWH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indian Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Clinical Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an
      intensive lifestyle or metformin to prevent or delay the development of diabetes in a high
      risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended
      early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced
      diabetes onset by 31%.

      The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP
      participants. This group of participants is nearly 50% minority and represents the largest
      IFG/IGT population ever studied. Clinically important research questions remain that focus
      on 1) durability of the prior DPP intervention, 2) determination of the clinical course of
      precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk
      factors and atherosclerosis, 3) close examination of these topics in men vs women and in
      minority populations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current DPPOS Executive Summary and protocol, as well as DPP protocol and lifestyle
      manuals and publications are available at: http://www.bsc.gwu.edu/dpp/index.htmlvdoc
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>development of diabetes.</measure>
    <time_frame>2008</time_frame>
    <description>Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level &gt;= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose &gt;= 200 mg/dL [11.1 mmol/L], after a 75 gram OGTT, and confirmed with a repeat test).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of aggregate microvascular complication</measure>
    <time_frame>2012-2013</time_frame>
    <description>Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on eGFR by CKD-Epi (&lt;45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (&gt; 30mg/gm, confirmed).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microvascular and cardiovascular disease risk factors</measure>
    <time_frame>2013</time_frame>
    <description>Blood pressure, lipids, medication use, weight, insulin resistance, HbA1c, physical activity by MAQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aging related outcomes - Cognitive and Physical Function</measure>
    <time_frame>2010 and 2012</time_frame>
    <description>Cognitive function defined as a composite measure constructed from tests of memory (English Spanish Verbal Learning Test) and executive function (word fluency and Digit Symbol Substitution Test ). Physical function assessed with the same two well-validated composite measures : the Short Physical Performance Battery (SPPB) and the Cardiovascular Health Study Frailty criteria. The SPPB is comprised of measures of 1) time to walk 3-4 meters, 2) balance, i.e., side-by-side stand, semi-tandem stand, and tandem stand, and 3) repeated chair stands. Frailty is classified based on 5 frailty characteristics: slow walking speed, low energy expenditure, exhaustion, weak grip strength, and unintentional weight loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subclinical atherosclerosis</measure>
    <time_frame>2012</time_frame>
    <description>Measured using coronary artery calcification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and economic analyses</measure>
    <time_frame>2002-2013</time_frame>
    <description>Quality of life measurements include Beck, SF-36, and QWB.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2776</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1 BLS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Boost / Lifestyle, previously Intensive Lifestyle during the DPP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 MLS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin / Lifestyle, previously the metformin treatment group during DPP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 GLS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group Lifestyle, previously placebo treated participants during DPP</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Group Lifestyle</intervention_name>
    <description>Quarterly group lifestyle sessions</description>
    <arm_group_label>1 BLS</arm_group_label>
    <arm_group_label>2 MLS</arm_group_label>
    <arm_group_label>3 GLS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered as 850mg twice per day</description>
    <arm_group_label>2 MLS</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Boost Lifestyle</intervention_name>
    <description>In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.</description>
    <arm_group_label>1 BLS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participation as a volunteer in the DPP.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M. Nathan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marinella Temprosa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Linder, MD, PhD</last_name>
    <affiliation>NIDDK Project Scientist</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George A Bray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Ehrmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Furlong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jefferson Medical College of Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Larsen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University Biostatistics Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald B Goldberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen P Hazuda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dana Dabelea, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward S Horton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Kahn, MB, ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samuel Dagogo-Jack, MD, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Science Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Molitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Barrett-Conner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>F. Xavier Pi-Sunyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Marrero, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanita Aroda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karol E Watson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sherita Hill Golden, MD, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David S Schade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of New Mexico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill Crandall, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trevor J Orchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Arakaki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Hawaii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Knowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SW Indian Center, NIDDK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santica M Marcovina, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David M Nathan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.dppos.org</url>
    <description>Study website</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00004992</url>
    <description>Clinical trials.gov entry for DPP</description>
  </link>
  <reference>
    <citation>Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.</citation>
    <PMID>11832527</PMID>
  </reference>
  <results_reference>
    <citation>Diabetes Prevention Program Research Group., Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Erratum in: Lancet. 2009 Dec 19;374(9707):2054.</citation>
    <PMID>19878986</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 16, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2002</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DPP</keyword>
  <keyword>IGT</keyword>
  <keyword>Prediabetes</keyword>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Macrovascular disease</keyword>
  <keyword>Microvascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
